8
IB1, FS No recommendation No recommendation
IB1, non-FS Extrafascial hysterectomy
(CB, In, W)
NACT if available, then
extrafascial hysterectomy
(CB, In, W)
Radical hysterectomy plus
PLND or radical hysterectomy
(see Note) with adjuvant RT or
RT with concurrent low-dose
chemotherapy (concurrent
chemoRT) if needed
(EB/CB, H, M-S)
ChemoRT or RT followed
by extrafascial or radical
hysterectomy (see Note) ±
PLND ± PANB
e
If no RT is available but
chemotherapy is available,
NACT may be used to shrink
the tumor to make it removable
by surgery (extrafascial or
modified radical hysterectomy
[see Note] ± PLND ± PANB
e
)
If the patient's tumor does not
shrink and is not resectable
with negative margins, palliative
measures, including best
supportive care, ± chemotherapy
should be offered
(EB/CB)
Note Evidence: (L, W) Wherever radical hysterectomy
with concurrent chemoRT is
listed as a surgical option above,
extrafascial hysterectomy
is recommended if there is
residual disease aer RT or
chemoRT with a boost of 68 Gy
or initial tumor >6 cm
Radical hysterectomy may be
used aer RT or chemoRT to a
dose of 50 Gy
Table 3. Recommendations for Stage IA, IB, and IIA Disease
(cont'd)
Type of Disease Basic Limited
Treatment
